XBiotech (XBiotech) EBIT per Share : $-1.35 (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XBiotech EBIT per Share?

XBiotech's EBIT per Share for the three months ended in Mar. 2024 was $-0.36. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.35.

During the past 3 years, the average EBIT per Share Growth Rate was -27.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was -17.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was -5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for XBiotech's EBIT per Share or its related term are showing as below:

XBIT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -73.3 Med: -12.5 Max: 25.5
Current: -27.6

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of XBiotech was 25.50% per year. The lowest was -73.30% per year. And the median was -12.50% per year.

XBIT's 3-Year EBIT Growth Rate is ranked worse than
80.09% of 1311 companies
in the Biotechnology industry
Industry Median: 3.5 vs XBIT: -27.60

XBiotech's EBIT for the three months ended in Mar. 2024 was $-10.85 Mil.

XBiotech EBIT per Share Historical Data

The historical data trend for XBiotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech EBIT per Share Chart

XBiotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.67

-0.59

-0.84

-1.13

-1.23

XBiotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.24	-0.44	-0.28	-0.28	-0.36

XBiotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

XBiotech's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-37.51	/	30.438
=	-1.23

XBiotech's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.853	/	30.444
=	-0.36

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.35

XBiotech (NAS:XBIT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

XBiotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of XBiotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

XBiotech (XBiotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

4XB:Germany 4XB:Germany

Address

5217 Winnebago Lane, Austin, TX, USA, 78744

Website

http://www.xbiotech.com

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Executives

Angela Hu	officer: Principle Financial Officer	5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard	director, 10 percent owner	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a.	10 percent owner	MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie	director, 10 percent owner	735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy	officer: VP of R&D	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han	officer: VP of Fin & HR, Secretary	8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut	10 percent owner	CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby	director	109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes	10 percent owner	RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam	director	56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin	director	77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman	officer: Sr.VP Corp. Strategy & Finance	8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson	officer: VP of Commercial Development	8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury	officer: VP of Business Development	8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough	officer: VP Clinical Operations	115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703